Lancet: Enquatabina uses tenofovira phenola amine for HIV infection prevention in high-risk populations.

!---- For HIV patients, the fenofoviraphenol has an advantage over noofovir didillin, which has antiviral effects and improved kidney and bone safety.recently researchers compared the efficacy and safety of Enquala-Benaitan with direoline or eiraphenol amine for HIV exposure prevention (PrEP).this study for Phase III non-effectiveness of the study, in Europe and North America high incidence of HIV, self-reporting of the past 12 weeks of male behavior of high-risk groups of HIV infection, on a 200 mg enquated a thina-based random acceptance of noofovir difuran (300 mg) or noofovir amine (25mg). The main outcome ofstudy is HIV infection.5,387 participants, of whom 2,694 were noofovir amine and 2,693 were for nofovir difuran.all participants completed 48 weeks of follow-up and 50% of the participants completed 96 weeks of follow-up, the results showed no significant difference in the prevention of HIV infection compared to tenofovir dithiratianinin, reaching a non-inferior endpoint.after 8,756 people -years of follow-up, 22 participants were diagnosed with HIV infection, of which 7 were in the aerate group (0.16 cases of infection/100 people-years) and 15 in the second furangroup (0.34 cases/100 people-years).both treatment syrating options were good, and few participants reported discontinuation due to adverse events.in all six pre-specified bone density and kidney biomarker safety endpoints, the fenofoviraphenol amine is superior to the pinosterin.studies have concluded that the effect of Enquatabin's use of tenofovira phenolic amine on hiv-high-risk population seisi-e-dispense is comparable to enquatabine's use of teofovirian, and the safety has more advantages..